2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 18, 2009, Pages 5359-5362

  Ramnauth, Jailall ^a   Surman, Mathew D ^b   Sampson, Peter B ^a   Forrest, Bryan ^a   Wilson, Jeff ^a   Freeman, Emily ^b   Manning, David D ^b   Martin, Fernando ^a   Toro, Andras ^a   Domagala, Megan ^a   Awrey, Donald E ^a   Bardouniotis, Elias ^a   Kaplan, Nachum ^a   Berman, Judd ^a   Pauls, Henry W ^a  

^a Affinium Pharmaceuticals Inc   (Canada)

^b ALBANY MOLECULAR RESEARCH INC   (United States)

Author keywords

2,3,4,5 Tetrahydro 1H pyrido; 2,3 e 1,4 diazepine; Antibacterial; Enoyl ACP reductase; FabI inhibitors; MRSA; Thigh infection model

Indexed keywords

1,4 DIAZEPINONE DERIVATIVE; 2,3,4,5 TETRAHYDRO 1H PYRIDO[2,3 B][1,4]DIAZEPINE; 2,3,4,5 TETRAHYDRO 1H PYRIDO[2,3 E][1,4]DIAZEPINE; DIAZEPINE DERIVATIVE; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ENZYME INHIBITOR; LINEZOLID; PROTEIN FABI; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE MODEL; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ESCHERICHIA COLI; HYDROGEN BOND; IC 50; INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; REACTION ANALYSIS; STAPHYLOCOCCUS AUREUS; STRUCTURE ANALYSIS; TRICLOSAN RESISTANT STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; AZEPINES; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; MICE; MODELS, MOLECULAR; PROTEIN BINDING; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

BACTERIA (MICROORGANISMS); HUMAN ECHOVIRUS 1; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 68949120854     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.094     Document Type: Article

References (19)

1. Yoneyama H., and Katsumata R. Biosci. Biotechnol., Biochem. 5 (2006) 1060
2. Leef M. Nature 431 (2004) 892
3. Walsh C. Nat. Rev. Microbiol. 1 (2003) 65
4. Projan S.J. Curr. Opin. Pharmacol. 2 (2002) 513
5. Campbell J.W., and Cronan Jr. J.E. Annu. Rev. Microbiol. 55 (2001) 305
6. Payne D.J., Warren P.V., Holmes D.J., Ji Y.O., and Longsdale J.T. Drug Discovery Today 6 (2001) 537
7. Heath R.J., White S.W., and Rock C.O. Prog. Lipid Res. 40 (2001) 467
8. Moir D.T. Curr. Drug Targets Infect. Disord. 5 (2005) 297
9. Chirala S.S., Huang W.Y., Jayakumar A., Sakai K., and Wakil S.J. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 5588
10. See for example the preceding paper in this issue and. Seefeld M.A., Miller W.H., Newlander K.A., Burgess W.J., DeWolf Jr. W.E., Elkins P.A., Head M.S., Jakas D.R., Janson C.A., Keller P.M., Manley P.J., Moore T.D., Payne D.J., Pearson S., Polizzi B.J., Qui X., Rittenhouse S.F., Uzinskas I.N., Wallis N.G., and Huffman W.F. J. Med. Chem. 46 (2003) 1627
11. Brinster S., Lamberet G., Stael B., Trieu-Cuot P., Gruss A., and Poyart C. Nature 458 (2009) 83
12. For a common left-hand side (i.e., benzothiophene) the ACD calculated solubility at pH 7.4 for the series 1, 9a and 20a is 0.12, 0.91 and 2.3 mg/ml, respectively.
13. Manning, D. D.; Xie, D.; Duong, T. N.; Decornez, H. Y.; Dorsey, M.; Awrey, D. E.; Kaplan, N.; Bardouniotis, E.; Clarke, T.; Berman, J.; Pauls, H. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October, 2004; F-318.
14. Case, D. A.; Pearlman, D. A.; Caldwell, J. W.; Cheatham, T. E., III; Wang, J.; Ross, W. S.; Simmerling, C. L.; Darden, T. A.; Merz, K. M.;. Stanton, R. V.; Cheng, A. L.; Vincent, J. J.; Crowley, M.; Tsui, V.; Gohlke, H.; Radmer, R. J.; Duan, Y.; Pitera, J.; Massova, I.; Seibel, G. L.; Singh, U. C.; Weiner P. K.; Kollman, P.A., AMBER 7, University of California, San Francisco15, 2002.
15. Pauls, H. W.; Manning, D. D., Xie, D.; Duong, T. N.; Decornez, H. Y.; Dorsey, M.; Awrey, D. E.; Kaplan, N.; Bardouniotis, E.; Clarke, T.; Berman, J.; In Structure-Guided Design, Synthesis and In Vivo Characterization of Inhibitors of Bacterial Fatty Acid Biosynthesis, 230th ACS National Meeting, Washington, DC, Aug. 28-Sept. 1, 2005; COMP 286.
16. Klapars A., Parris S., Anderson K.W., and Buchwald S.L. J. Am. Chem. Soc. 126 (2004) 3529
17. S. aureus FabI inhibition assays were carried out in half area 96-well plates, with an enzyme concentration of 3 nM enzyme, as described in Payne, D. J.; Miller, W. H.; Berry, V.; Brosky, J.; Burgess, W. J.; Chen, E.; DeWolf, W. E., Jr.; Fosberry, A. P.; Greenwood, R.; Head, M. S.; Heerding, D.; Janson, C. A.; Jaworski, D. D.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Newlander, K. A.; Pearson, S.; Polizzi, B. J.; Qiu,X.; Rittenhouse, S. F.; Slater-Radosti, C.; Salyers, K. L.; Seefeld, M. A.; Smyth, M. G.; Takata, D. T.; Uzinskas, I. N.; Vaidya, K.; Wallis, N. G.; Winram, S. B.; Yuan, C. C. K.; Huffman, W. F. Antimicrob Agents Chemother. 2002, 46, 3118.E. coli FabI inhibition assays were carried out in half area 96-well plates containing 150 μL of 100 mM MOPS pH 7.2, 50 mM ammonium acetate, 3% glycerol, 25 μM crotonyl-ACP, 50 μM NADH, and 0.5 nM enzyme. Consumption of NADH was monitored at 340 nm and a titration of standard compound was included on each dose response plate as a positive control.
18. MIC testing was performed according to CLSI guidelines using the microdilution method in 96-well plates: National Committee for Clinical Laboratory Standards. 2003. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 5th ed., Approved Standard M7-A6. NCCLS, Wayne, PA, USA.
19. 5 CFU of S. aureus 29213. Two hours post infection single oral doses of compounds were administered (time 0). Efficacy was determined 24 hours post-dosing and expressed as the average change in log CFU per thigh compared to time 0: Maglio D, Banevicius MA, Sutherland C, Babalola C, Nightingale CH, Nicolau DP. 2005. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model. Antimicrob Agents Chemother. 49, 276-280.